PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

omalizumab

Verify with FDA → · CMS NADAC pricing →

Brand names: Xolair

Anti-IgE Monoclonal Antibody Rx

Xolair is a medicine that can help with asthma, nasal polyps, food allergies, and chronic hives. It works by blocking a substance in your body called IgE.

What it does

Xolair can treat moderate to severe asthma in people 6 years and older who have allergies.

Common side effects

Joint pain, General pain, Leg pain

Key warnings

Xolair can cause a severe allergic reaction called anaphylaxis, even after the first dose or after you have been taking it for a year or more.

How It Works

Xolair is a special type of medicine called an anti-IgE monoclonal antibody. It blocks immunoglobulin E (IgE) in your body. IgE is a substance that causes allergic reactions and inflammation.

How to Take It

Xolair is given as a shot under the skin (subcutaneous injection). The dose and how often you get it (every 2 or 4 weeks) depends on your IgE levels and weight. Your doctor will test your IgE levels before you start Xolair. Doses may need to be adjusted if your weight changes a lot.

Pregnancy & Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant. It is not known how Xolair will affect your unborn baby, but poorly controlled asthma during pregnancy can be risky. Talk to your doctor about the risks and benefits of taking Xolair during pregnancy.

Missed Dose

If you miss a dose of Xolair, call your doctor right away to reschedule your injection. Do not double your next dose.

Storage

Keep Xolair in the refrigerator between 36°F and 46°F (2°C to 8°C) in its original carton, away from direct sunlight. It can be taken out of the fridge for a total of 2 days, but do not leave it above 77°F (25°C). Do not freeze Xolair.

Side Effects (from patient reports)

Based on 83,679 FDA adverse event reports.

Asthma
11,602
Hives
10,326
No side effect
10,204
Using the medicine for something it's not approved for
9,929
Difficulty breathing
9,876
The medicine is not working
7,779
Cough
6,767
Itching
5,942
Tiredness
5,825
Feeling unwell
5,429

FDA Adverse Event Report Analysis

Detailed analysis of 79,748 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.

Total Reports

79,748

Death-Related Reports

2,390

Hospitalization Reports

15,129

Top Indication

Asthma

Gender Distribution

Female 52,705 (73%)
Male 18,979 (26%)

Age Distribution

0–17 3,184
18–44 12,576
45–64 15,541
65–74 6,481
75+ 2,998

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 ASTHMA 11,601
2 URTICARIA 10,326
3 NO ADVERSE EVENT 10,204
4 OFF LABEL USE 9,929
5 DYSPNOEA 9,876
6 DRUG INEFFECTIVE 7,778
7 COUGH 6,767
8 PRURITUS 5,942
9 FATIGUE 5,824
10 MALAISE 5,429
11 WHEEZING 5,239
12 HEADACHE 5,206
13 PNEUMONIA 4,979
14 PAIN 4,103
15 ANAPHYLACTIC REACTION 3,984

Reactions in Death Reports

DEATH 1,455
ASTHMA 301
PNEUMONIA 179
DYSPNOEA 165
MALAISE 129
FATIGUE 111
OFF LABEL USE 105
ASTHENIA 101
COUGH 99
MYOCARDIAL INFARCTION 86

Reactions in Hospitalization Reports

ASTHMA 5,346
DYSPNOEA 4,226
COUGH 3,043
PNEUMONIA 2,699
MALAISE 2,262
WHEEZING 2,208
FATIGUE 2,039
URTICARIA 1,872
HEADACHE 1,727
DRUG INEFFECTIVE 1,707

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Xolair can cause a severe allergic reaction called anaphylaxis, even after the first dose or after you have been taking it for a year or more. This reaction can cause trouble breathing, low blood pressure, fainting, hives, and swelling of the throat or tongue. Because of this risk, your doctor should give you Xolair in a healthcare setting where they can treat anaphylaxis. Watch for signs of anaphylaxis after each Xolair injection and seek immediate medical care if symptoms occur.

Common Questions

Can Xolair cure my asthma?
No, Xolair does not cure asthma. It helps to control your symptoms.
Can I use Xolair for a sudden asthma attack?
No, Xolair is not for sudden asthma attacks. Use your rescue inhaler for those.
How long does it take for Xolair to work?
It may take several weeks or months to see the full effects of Xolair.
Will Xolair get rid of my nasal polyps?
Xolair can help shrink nasal polyps and improve your symptoms.
Do I still need to avoid foods I am allergic to while taking Xolair?
Yes, you must still avoid foods you are allergic to, even while taking Xolair.
Can Xolair completely prevent allergic reactions to food?
No, Xolair reduces the risk of reactions, but it doesn't eliminate them completely.
Can I stop taking my other allergy medicines while on Xolair?
Do not stop taking any of your other medicines unless your doctor tells you to.
What should I do if I have an allergic reaction after getting a Xolair injection?
Seek immediate medical care if you have any signs of an allergic reaction.
Will Xolair cause me to gain weight?
Weight gain is not a common side effect of Xolair.
Can I give myself Xolair injections at home?
Your doctor will decide if you can give yourself Xolair injections at home.
What are the common side effects of omalizumab?
The most commonly reported side effects of omalizumab include Joint pain, General pain, Leg pain, Tiredness, Dizziness. Based on 83,679 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
What drug class is omalizumab?
omalizumab belongs to the Anti-IgE Monoclonal Antibody drug class. It requires a prescription (Rx). Xolair can treat moderate to severe asthma in people 6 years and older who have allergies.
Is omalizumab safe during pregnancy?
Tell your doctor if you are pregnant or plan to become pregnant. It is not known how Xolair will affect your unborn baby, but poorly controlled asthma during pregnancy can be risky. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in Anti-IgE Monoclonal Antibody

Other drugs grouped near omalizumab — same-class peers and common alternatives.

Compare omalizumab vs aclidinium side-by-side →

Medication Guides

Related Health & Safety Data

Save on omalizumab

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for omalizumab

The FDA label for omalizumab (sold under brand names such as Xolair) classifies it as a prescription-only medication in the Anti-IgE Monoclonal Antibody class. Xolair can treat moderate to severe asthma in people 6 years and older who have allergies. Official labeling lists 24 commonly reported side effects, including Joint pain, General pain, Leg pain.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 83,679 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: December 2, 2025

All federal data sources used on this page